NewsBenzingaMangoceuticals (MGRX) Shares Fall 12% After Hours: Here's Why Mangoceuticals (MGRX) Shares Fall 12% After Hours: Here's Why Benzinga 2026.10.02 05:22 (GMT+0) Open on Benzinga Other news 'Amazon Seeks To Offload $8bn of Nvidia Chips To Investors' - FT 'Broadcom Starts Amassing $60 Billion to Fund Chips for Anthropic' - Bloomberg Summit Therapeutics, AstraZeneca And Daiichi Sankyo Announce Clinical Trial Collaboration To Evaluate Ivonescimab With TROP2-Directed ADC Datroway Across Multiple Tumor Types, Starting With Phase III First-Line Triple-Negative Breast Cancer Study SMX Stock Climbs Over 38% After-Hours: What's Going On? Reported Earlier, Phillips Edison Reaffirms 2026 Core FFO Per Share Guidance At $2.73-$2.79, Up 6.2% YoY At Midpoint, Raises Gross Acquisitions Guidance To $600M-$700M Reported Earlier, Cullinan Therapeutics Initiates NDA Submission For Zipalertinib Plus Chemotherapy In First-Line EGFR Exon 20 Insertion NSCLC Under FDA RTOR Program After Phase 3 REZILIENT3 Trial Met Primary Endpoint
Summit Therapeutics, AstraZeneca And Daiichi Sankyo Announce Clinical Trial Collaboration To Evaluate Ivonescimab With TROP2-Directed ADC Datroway Across Multiple Tumor Types, Starting With Phase III First-Line Triple-Negative Breast Cancer Study
Reported Earlier, Phillips Edison Reaffirms 2026 Core FFO Per Share Guidance At $2.73-$2.79, Up 6.2% YoY At Midpoint, Raises Gross Acquisitions Guidance To $600M-$700M
Reported Earlier, Cullinan Therapeutics Initiates NDA Submission For Zipalertinib Plus Chemotherapy In First-Line EGFR Exon 20 Insertion NSCLC Under FDA RTOR Program After Phase 3 REZILIENT3 Trial Met Primary Endpoint
